

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

RESEARCH LETTER

COVID-19 and Abdominal Aortic Aneurysm Intervention: When to Defer and When to Operate

Recommendations concerning the management of abdominal aortic aneurysms (AAAs) \geq 5.5 cm during the COVID-19 pandemic from societies, such as the Society for Vascular Surgery and the Vascular Society for Great Britain & Ireland, recommend deferring repair. However, neither document quantifies the optimal deferral time periods, stating that clinicians should consider factors such as COVID-19 transmission risk and rupture risk. The European Society for Vascular Surgery AAA guidelines specify that rapidly growing AAAs (\geq 1 cm/year) should prompt fast track vascular referral;¹ these recommendations were developed and published before the COVID-19 pandemic. McGuinness et al. recently reported the results of their risk modelling to address this issue.² They include patient, AAA, and COVID-19 risk parameters. This analysis, however, was limited owing to the data on which they based annual rupture risk, which seemed to be an overestimation; and their estimation of peri-operative COVID-19 related mortality, which seemed to be an underestimation.

Annual AAA rupture rates used by McGuinness *et al.* were based on a prospective cohort study of 198 patients turned down for elective repair between 1995 and 2000: 9.4%, 10.2%, and 32.5% for 5.5 – 5.9 cm, 6.0 – 6.9 cm, and \geq 7 cm AAAs respectively.² Peri-operative COVID-19 related mortality was assumed to be equivalent to community COVID-19 mortality risk.²

More robust pooled data are available on which to base estimates of rupture rates. The meta-analysis by Parkinson *et al.* included 1 514 patients from 11 studies.³ They reported significantly lower pooled annual rupture rates: 3.5%, 4.1%, and 6.3% for 5.5 – 6 cm, 6.1 – 7 cm, and > 7 cm AAAs respectively. Additionally, there are meta-analysed data available describing post-operative COVID-19 related mortality.⁴

The aim was to conduct risk model analysis using these up to date data, hypothesising that more patient groups would be better served by deferral of repair than McGuinness *et al.* suggest. The model calculates the "optimal strategy" (repair or deferral) at different timepoints from when elective repair is considered (3, 6, 9, and 12 months) based on baseline, rupture, operative, and COVID-19 related mortality risks.

Decision tree analysis was performed using data from Parkinson *et al.*³ to inform annual rupture risk and data from Brown *et al.*⁴ to inform peri-operative COVID-19 related mortality. All other model parameters were identical to those used by McGuinness *et al.*² Analyses were conducted using the statistical software Amua (version 0.3.0). Baseline annual mortality risk parameters were based on the Center for Disease Control and Prevention's

2016 National Vital Statistics Reports. COVID-19, open and endovascular AAA repair, and AAA rupture related mortality risk estimates were stratified by age.^{2,4} Risk of COVID-19 transmission was stratified by community COVID-19 prevalence and in patient/community status, with nosocomial transmission rate estimated as twice community transmission risk.²

The results suggest that deferral is preferred to open repair for all AAAs at three months (Fig. 1). Open repair becomes preferable to deferral at six months only in younger patients (< 65 years of age) with aneurysms > 7 cm (when COVID-19 transmission risk is low).

Deferral is preferred to endovascular repair at three months in most scenarios. Endovascular repair becomes preferred to deferral at six months for the majority when COVID-19 transmission risk is low.

This analysis addresses an obvious deficiency in the current guidance by major vascular societies, by accounting for age, repair type, and COVID prevalence. The results support deferral for many patients but highlight that "one size does not fit all", specifying when repair becomes appropriate and for whom.

Evidence on AAA diameter at the time of rupture would suggest that a sizable proportion of ruptures occur in AAAs > 7.0 cm. The IMPROVE trial reported that 78.7% of their cohort had AAA > 7.0 cm.⁵ Similarly, Laine *et al.* report that only 8% of ruptured (r)AAAs were below 5.5 cm at the time of rupture.⁶ However, such studies do not further inform yearly rupture risk since they only include patients with a rAAA, without a "denominator" (non-rAAA data) available.

This analysis is limited as individual patient comorbidities are not considered, which could significantly influence AAA repair, rupture, and COVID-19 related mortality risks. As such, the results should be used to complement existing mortality risk estimations. Data are based on patients that were turned down for repair: rupture risk may differ for patients considered suitable/fit for repair. The model does not consider relevant factors such as the variability in provision and effectiveness of COVID-19 low "green pathways". However, by providing optimal strategies at differing COVID-19 transmission risk levels, ranging from 0.01% (0.02% nosocomial) to 30% (60% nosocomial), clinicians can interpret the results that most closely align their current local transmission risk. Units with efficient green pathways could use the "0.01%" transmission template as an approximation to their risk. Lastly, the model is not yet validated, and this should be considered when used to support clinical decision making.

These results are a framework for clinicians to time planned intervention for patients with AAAs \geq 5.5 cm. For many patients in areas of low community COVID-19 transmission risk, deferral of repair as suggested by current guidance may increase mortality risk.

Infection probability 0.01% (0.02% nosocomia) Age Aneurysm size - cm 5.5-5.9 6-6.9 7 50-59 6 6 6 60-64 6 6 6 70-74 7 7 7 80-84 6 6 6	Inf Age 50–59 60–64 65–69 70–74	ection pro (2% nos Aneu	obability						1				
Aneurysm size - cm 5.5-5.9 6-6.9 7 50-59 - - 6 60-64 - - 6 65-69 - - 7 70-74 - - 7 75-79 - - - 80-84 - - 1	Age 50–59 60–64 65–69 70–74	Aneu	n probability 0.01% 12% nosocomial) (2% nosocomial)					Infection probability 0.01% (0.02% nosocomial)					
5.5-5.9 6-6.9 7 50-59 60-64 70-74 75-79 80-84	50–59 60–64 65–69 70–74	-	rysm size	e – cm	Age	Aneu	rysm size	– cm	Age	Aneu	rysm size	e – cm	
30-39	60–64 65–69 70–74	5.5-5.9	6-6.9	7	50.50	5.5-5.9	6-6.9	7	50.50	5.5-5.9	6-6.9	7	
00-04 ■ 65-69 ■ 70-74 ■ 75-79 ■ 80-84 ■ ≥85 ■	65–69 70–74				50-59				50-59				
000000000000000000000000000000000000	70-74				65-69	x	x		65-69	x	x		
75-79 80-84 ≥85					70-74	X	X		70-74	X	X		
80-84	75-79				75-79	Y	0		75-79	Y	0		
≥85	80-84				80-84	Y	Y		80-84	Y	Y		
	≥85				≥85				≥85				
(20% nosocomial)	Infe	Infection probability 30% (60% nosocomial)				Infection probability 10% (20% nosocomial)				Infection probability 30% (60% nosocomial)			
Aneurysm size – cn		Aneurysm size – cm			Aneurysm size – cm				Aneurysm size – cm				
5.5-5.9 6-6.9 7	Age	5.5-5.9	6-6.9	7	Age	5.5-5.9	6-6.9	7	Age	5.5-5.9	6-6.9	7	
50–59	50-59				50-59				50–59				
60–64	60-64				60-64				60–64	Х	Х		
65–69	65-69				65-69	X	X		65-69	X	X		
70–74	70-74	X	X		70-74	X	X		70-74	0	0		
75–79	75-79	X	X		75-79	Y	Y	v	75-79	Y	Y	X	
80-84 X	80-84	X	X		80-84			A V	80-84			X V	
Infection probability 0.01%	EVAR Inf	AR Infection probability 1%			Open Infection probability 0.01%				repair Infection probability 1%				
(0.02% nosocomial)		(2% nosocomial)).02% no	socomial	.)		(2% nose	ocomial)		
Age Aneurysm size – cn	Age	Aneu	rysm size	e – cm	Age	Aneu	rysm size	- cm	Age	Aneu	rysm size	- cm	
5.5-5.9 6.0-7.0 >	7	5.5-5.9	6.0-7.0	>7	50.50	5.5-5.9	6.0-7.0 v	>7	50.50	5.5-5.9	6.0-7.0	>7	
60-64	60 64				1 20-28	0	А	А	00-39	0			
00=04	100-04				60 64	0	x	x	60.64		0	x	
65-69 X X	65-69	I X	x		60-64 65-69	O Y	X	X	60-64 65-69		O Y	X	
65–69 X X 70–74 X X	65–69 70–74	X	X X		60-64 65-69 70-74	О Ү Ү	X Y Y	X 0 0	60–64 65–69 70–74		0 Y Y	X 0 0	
65-69 X X 70-74 X X 75-79 X X	65–69 70–74 75–79	X X X	X X X		60-64 65-69 70-74 75-79	0 Y Y	X Y Y	X 0 0	60–64 65–69 70–74 75–79		0 Y Y	X 0 0	
65-69 X X 70-74 X X 75-79 X X 80-84 X X	65–69 70–74 75–79 80–84	X X X X	X X X X	X	60-64 65-69 70-74 75-79 80-84	O Y Y	X Y Y	X 0 0	60–64 65–69 70–74 75–79 80–84		0 Y Y	X 0 0	
65-69 X X 70-74 X X 75-79 X X 80-84 X X ≥85 O O X	65-69 70-74 75-79 80-84 ≥85	X X X X O	X X X X X X	X X	60-64 65-69 70-74 75-79 80-84 ≥ 85	0 Y Y	X Y Y	X 0 0	60-64 65-69 70-74 75-79 80-84 ≥85		О Ү Ү	X 0	
65–69 X X 70–74 X X 75–79 X X 80–84 X X ≥ 85 O O X Infection probability 10% (20% nosocomial)	65-69 70-74 75-79 80-84 ≥85 Infe	X X X O ction pro (60% nos	X X X X bability : scomial)	X X 30%	60-64 65-69 70-74 75-79 80-84 ≥85 Infee	O Y Y Ction pro 20% nos	X Y Y bability 1 cocomial)	X 0 0	60-64 65-69 70-74 75-79 80-84 ≥85 Infe	ction pro (60% nos	O Y Y bability 3 ocomial)	X O O 30%	
65-69 X X 70-74 X X 75-79 X X 80-84 X X ≥85 O O X Infection probability 10% (20% nosocomial) Aneurysm size - cn cn	$\begin{array}{c} 65-69\\ 70-74\\ 75-79\\ 80-84\\ \geq 85\\ Infe\\ 1\\ Age \end{array}$	X X X O ection pro (60% nos Aneu	X X X X bability : coomial) rysm size	X X 30%	60-64 65-69 70-74 75-79 80-84 ≥85 Infee	O Y Y etion pro 20% nos Aneu	X Y Y bability 1 cocomial)	X 0 0	60-64 65-69 70-74 75-79 80-84 ≥85 Infe	ction pro (60% nos Aneur	O Y Y bability 3 ocomial)	X 0 0	
65-69 X X 70-74 X X 75-79 X X 80-84 X X ≥ 85 O O X Infection probability 10% (20% nosocomia) Age Aneurysm size - cm 5-5-5-9 6.0-7.0 ≥	65-69 70-74 75-79 80-84 ≥ 85 Infe	X X X X O ction pro (60% nos Aneu 5.5–5.9	X X X X bability : socomial) rysm size 6.0–7.0	X X 30% 2 - cm >7	60-64 65-69 70-74 75-79 80-84 ≥85 Infee 0 Age	0 Y Y :tion pro 20% nos Aneu 5.5–5.9	X Y Y bability 1 cocomial) rysm size 6.0–7.0	X 0 0 	60-64 65-69 70-74 75-79 80-84 ≥85 Infe	ction pro (60% nos Aneur 5.5–5.9	O Y Y bability 3 ocomial) rysm size 6.0–7.0	X 0 0 30% - cm >7	
65-69 X X 70-74 X X T 75-79 X X X 80-84 X X I ≥ 85 O O X Infection probability 10% (20% nosoconia) X I Age Aneurysm size - cm 5.5-5.9 6.0-7.0 > 50-69 I I I I I	65-69 70-74 75-79 80-84 ≥ 85 Infe 7 7 50-59	X X X X O ction pro (60% nos Aneu 5.5–5.9 X	X X X X bability : coomial) rysm size 6.0–7.0 X	X X 30% = - cm > 7	60-64 65-69 70-74 75-79 80-84 ≥ 85 Infec Age 50-59	0 Y Y 20% nos Aneu 5.5-5.9	X Y Y bability 1 ocomial) rysm size 6.0–7.0	X 0 0 10% - cm >7 0	60-64 65-69 70-74 75-79 80-84 ≥85 Infe Age 50-59	ction pro (60% nos Aneu 5.5–5.9	O Y Y bability 3 ocomial) rysm size 6.0–7.0	X 0 0 30% - cm >7	
	$\begin{array}{c} 65-69\\ 70-74\\ 75-79\\ 80-84\\ \geq 85\\ 1 \\ 85\\ 1 \\ 7 \\ 50-59\\ 60-64\\ 65-69\end{array}$	X X X X O ction pro (60% nos Aneu 5.5–5.9 X X X	X X X X bability 3 cocomial) rysm size 6.0–7.0 X X X	X X 30% >7	$ \begin{array}{r} \hline & 0 & -64 \\ & 65 & -69 \\ & 70 & -74 \\ & 75 & -79 \\ & 80 & -84 \\ & \geq 85 \\ & Infect \\ & 4ge \\ & 50 & -59 \\ & 60 & -64 \\ & 65 & -69 \\ & 65 & -69 \\ & 65 & -69 \\ & 65 & -69 \\ & 65 & -69 \\ & 65 & -69 \\ & 65 & -69 \\ & 65 & -69 \\ & 65 & -69 \\ & 65 & -69 \\ & 65 & -69 \\ & 65 & -69 \\ & 65 & -69 \\ & 75 & -75 \\ $	0 Y Y 20% nos Aneu 5.5–5.9	X Y Y bability 1 cocomial) rysm size 6.0–7.0	X 0 0 .0% - cm >7 0 0	60-64 65-69 70-74 75-79 80-84 ≥85 Infe Age 50-59 60-64 65-69	ction pro (60% nos Anew 5.5–5.9	O Y Y bability 5 ocomial) rysm sizee 6.0–7.0	X 0 0 30% - cm >7	
$\overline{65-69}$ X X 70-74 X X 75-79 X X ≥85 0 0 X 285 0 0 X Infection probability 10% (20% nosocomial) Age Aneurysm size - cn $\overline{5.5-59}$ 6.0-7.0 > $\overline{50-59}$ 0 0 X 70-74 0 0 X	$\begin{array}{c c} 65-69\\ 70-74\\ 75-79\\ 80-84\\ \geq 85\\ Infe 1 Age 7 50-59 60-64 65-69 70-74$	X X X X O Cetion pro (60% nos 60% nos 5.5–5.9 X X X	X X X X bability 3 cocomial) rysm size 6.0–7.0 X X X	X X 30% 2 - cm >7 0 0	$\begin{array}{c} \hline & \hline & \hline & \hline \\ 60-64 \\ 65-69 \\ 70-74 \\ \hline & 75-79 \\ 80-84 \\ \geq 85 \\ \hline & Infec \\ \hline & \\ 85 \\ \hline & \\ 50-59 \\ 60-64 \\ 65-69 \\ \hline & \\ 65-69 \\ 70-74 \end{array}$	O Y Y Stion pro 20% nos Aneu 5.5–5.9	X Y Y bability 1 cocomial) rysm size 6.0–7.0	X 0 0 0 0 0 0 2 - cm >7 0 0 0	60-64 65-69 70-74 75-79 80-84 ≥ 85 Infe 50-59 60-64 65-69 70-74	ction pro (60% nos Aneu 5.5–5.9	O Y Y bability 3 ocomial) rysm size 6.0–7.0	X 0 0 30% - cm >7	
65-69 X X 70-74 X X 75-79 X X ≥85 O O ≥85 O O X Threeton probability 10% (20% nosocontal) Nosocontal) Nosocontal) Age Aneurysm size - cn S 50-59 60-64 O Nosocontal) 60-64 O O X 70-74 O O X	$\begin{array}{c c} 65-69\\ 70-74\\ 75-79\\ 80-84\\ \geq 85\\ Infe\\ 1 \\ Age\\ 7 \\ 50-59\\ 60-64\\ 65-69\\ 70-74\\ 75-79\end{array}$	X X X X O Cetion pro (60% nos 60% nos 60% nos 5.5–5.9 X X X	X X X X bability 3 coomial) rysm size 6.0–7.0 X X X	X X 30% >- cm >7 0 0 0 0 0 7	$\begin{array}{c} \hline & 0 \\ \hline & 0 \\ \hline & 60 \\ \hline & 65 \\ \hline & 65 \\ \hline & 70 \\ \hline & 77 \\ \hline & 75 \\ \hline & 79 \\ \hline & 80 \\ \hline & 84 \\ \hline & 285 \\ \hline & Infec \\ \hline & 85 \\ \hline & 106 \\ \hline & 85 \\ \hline & 106 \\ \hline & 85 \\ \hline & 106 \\ \hline &$	O Y Y Stion pro 20% nos Aneu 5.5–5.9	X Y Y bability 1 cocomial) rysm size 6.0–7.0	X 0 0 0 0 0 0 0 0 0	60-64 65-69 70-74 75-79 80-84 ≥ 85 Infe 50-59 60-64 65-69 70-74 75-79	ction pro (60% nos Aneu 5.5–5.9	O Y Y bability 3 ocomial) rysm size 6.0–7.0	X 0 0 30% - cm >7	
65-69 X X 70-74 X X 75-79 X X 80-84 X X ≥85 O O X ≥85 O O X 1mt=::::::::::::::::::::::::::::::::::::	65-69 70-74 75-79 80-84 ≥85 80-84 ≥85 10 7 50-59 60-64 60-64 65-69 70-74 75-79 80-84	X X X X O Cotion pro (60% nos (60% nos (5.5–5.9 X X X X	X X X X bability 3 cocomial) rysm size 6.0–7.0 X X X	X X 30% - cm >7 0 0 0 0 0 7 Y	a b a b a b b b c b c b c b c b c b c b c b c b c b c c	0 Y Y 20% nos Aneu: 5.5–5.9	X Y Y bability 1 occomial) rysm size 6.0–7.0	X 0 0 0% - cm >7 0 0	60-64 65-69 70-74 75-79 80-84 ≥85 Infe 50-59 60-64 65-69 70-74 75-79 80-84	ction pro (60% nos Aneu 5.5–5.9	O Y Y bability 3 ocomial) rysm size 6.0–7.0	x 0 0 30% - cm >7	

REFERENCES

- Wanhainen A, Verzini F, Van Herzeele I, Allaire E, Brown M, Cohnert T, et al. European Society for Vascular Surgery (ESVS) 2019 clinical practice guidelines on the management of abdominal aorto-iliac artery aneurysms. *Eur J Vasc Endovasc Surg* 2019;57:8–93.
- 2 McGuinness B, Troncone M, James LP, Bisch SP, Iyer V. Reassessing the operative threshold for abdominal aortic aneurysm repair in the context of coronavirus disease 2019. *J Vasc Surg* 2020;**72**:E345.
- **3** Parkinson F, Ferguson S, Lewis P, Williams IM, Twine CP. Rupture rates of untreated large abdominal aortic aneurysms in patients unfit for elective repair. *J Vasc Surg* 2015;**61**:1606–12.
- 4 Brown WA, Moore EM, Watters DA. Mortality of patients with COVID-19 who undergo an elective or emergency surgical procedure: a systematic review and meta-analysis. *ANZ J Surg* 2021;91:33–41.
- **5** IMPROVE trial investigators. Endovascular or open repair strategy for ruptured abdominal aortic aneurysm: 30 day outcomes from IMPROVE randomised trial. *BMJ* 2014;**348**:f7661.

6 Laine MT, Laukontaus S, Kantonen I, Venermo M. Population-based study of ruptured abdominal aortic aneurysm. *Br J Surg* 2016;103: 1634–9.

> Brenig L. Gwilym^{a,}*, Frances Kent^a, Christopher P. Twine^b, David C. Bosanquet^a

^aAneurin Bevan University Health Board, UK

^bBristol Centre for Surgical Research, Bristol Medical School, University of Bristol, Bristol, England, UK

^{*}Corresponding author. Royal Gwent Hospital, Cardiff Road, Newport NP20 2UB, UK.

Email-address: blgwilym@gmail.com (Brenig L. Gwilym)

Available online 4 June 2021

© 2021 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.